DUBLIN–(BUSINESS WIRE)–The “Meningococcal Vaccine Market by Serogroup, Vaccine Type and End User: Global Opportunity Analysis and Industry Forecast, 2018-2026” report has been added to ResearchAndMarkets.com’s offering.

According to this report the global meningococcal vaccines market size was valued at $1,935.54 million in 2018, and is projected to reach $4.19 billion by 2026, registering a CAGR of 9.5% from 2019 to 2026.

Bacterial infections can be prevented by immunization and therefore, immunization is crucial. Neisseria meningitidis, is a virus that causes diseases such as meningitis, bacteremia (meningococcemia), and bacteremia pneumonia. However, these infectious diseases can be prevented by the use of meningococcal vaccines. Meningococcal vaccines are administered to both children and adults in a pattern of two doses to ensure complete immunization. There are three different types of meningococcal vaccines such as conjugate, polysaccharide, and subcapsular meningococcal vaccines.

Rise in immunization programs worldwide is the major factor that boost the growth of the meningococcal vaccine market. In addition, factors such as surge in awareness related to the use of meningococcal vaccines and increase in adoption of vaccination across the globe fuel the growth of the meningococcal vaccine market. However, high monetary inputs associated with manufacture of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the meningococcal vaccine market growth during the forecast period.

The global meningococcal vaccine market is segmented on the basis of serotype, vaccine types, and end user. (Read more…) On the basis of serotype, the market is classified into Men ACYW, Men B/BC, Men C/CY, Men AC, and Men A. By vaccine type, it is divided into conjugate, polysaccharide, and subcapsular. On the basis of end user, it is segmented into pediatric, adult, and traveler. Based on region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, the UK, Spain, France, the Netherlands, and rest of Europe), Asia-Pacific(China, Australia, and rest of Asia-Pacific), and LAMEA (Latin America.

The developing economies offer lucrative opportunities for meningococcal vaccine providers to expand their business. The constantly evolving healthcare industry drives the growth of the market in the developing economies such as Africa, China, and others ca, the Middle East, and Africa).

Key Benefits

• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Key Findings

• As per the serotype, the MenACWY vaccine segment is accounted for the highest market share of 54% in 2018 and is anticipated to grow at a CAGR of 11.7% during the forecast period.
• On the basis of the vaccine type, the conjugate vaccine segment accounted for the largest market share and is anticipated to be the fastest growing segment at a CAGR of 10.2%.
• By end user, the hospitals & clinics segment is expected to grow at the highest CAGR of 11.6% from 2019 to 2026, in terms of value.
• Region wise, North America was the major shareholder and accounted for 49.84% of the meningococcal vaccine market share in 2018.

Market Dynamics

Drivers

• Increase in Outbreaks of Meningococcal Disease
• Surge in Immunization Programs Across the Globe
• Increase in Research and Development for Vaccine Technology

Restraint

• Longer Timelines Required for Vaccine Production
• High Costs Associated With the Development of Vaccines

Opportunities

• Growth Opportunities in the Emerging Markets
• Increase in Healthcare Spending
• Increase in Research and Development for Meningococcal Vaccines

Key Players Profiled

• Bio-Manguinhos
• Bio-Med Pvt. Limited
• Chongqing Zhifei Biological Products Co., Ltd.
• GlaxoSmithKline Plc
• Hualan Biological Engineering Inc.
• Incepta Pharmaceuticals Ltd.
• Pfizer INC
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd
• Walvax Biotechnology Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/dwjcj6

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Meningococcal Vaccine Market by Serogroup, Vaccine Type and End User: Global Opportunity Analysis and Industry Forecast, 2018-2026” report has been added to ResearchAndMarkets.com’s offering.

According to this report the global meningococcal vaccines market size was valued at $1,935.54 million in 2018, and is projected to reach $4.19 billion by 2026, registering a CAGR of 9.5% from 2019 to 2026.

Bacterial infections can be prevented by immunization and therefore, immunization is crucial. Neisseria meningitidis, is a virus that causes diseases such as meningitis, bacteremia (meningococcemia), and bacteremia pneumonia. However, these infectious diseases can be prevented by the use of meningococcal vaccines. Meningococcal vaccines are administered to both children and adults in a pattern of two doses to ensure complete immunization. There are three different types of meningococcal vaccines such as conjugate, polysaccharide, and subcapsular meningococcal vaccines.

Rise in immunization programs worldwide is the major factor that boost the growth of the meningococcal vaccine market. In addition, factors such as surge in awareness related to the use of meningococcal vaccines and increase in adoption of vaccination across the globe fuel the growth of the meningococcal vaccine market. However, high monetary inputs associated with manufacture of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the meningococcal vaccine market growth during the forecast period.

The global meningococcal vaccine market is segmented on the basis of serotype, vaccine types, and end user. (Read more…) On the basis of serotype, the market is classified into Men ACYW, Men B/BC, Men C/CY, Men AC, and Men A. By vaccine type, it is divided into conjugate, polysaccharide, and subcapsular. On the basis of end user, it is segmented into pediatric, adult, and traveler. Based on region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, the UK, Spain, France, the Netherlands, and rest of Europe), Asia-Pacific(China, Australia, and rest of Asia-Pacific), and LAMEA (Latin America.

The developing economies offer lucrative opportunities for meningococcal vaccine providers to expand their business. The constantly evolving healthcare industry drives the growth of the market in the developing economies such as Africa, China, and others ca, the Middle East, and Africa).

Key Benefits

• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Key Findings

• As per the serotype, the MenACWY vaccine segment is accounted for the highest market share of 54% in 2018 and is anticipated to grow at a CAGR of 11.7% during the forecast period.
• On the basis of the vaccine type, the conjugate vaccine segment accounted for the largest market share and is anticipated to be the fastest growing segment at a CAGR of 10.2%.
• By end user, the hospitals & clinics segment is expected to grow at the highest CAGR of 11.6% from 2019 to 2026, in terms of value.
• Region wise, North America was the major shareholder and accounted for 49.84% of the meningococcal vaccine market share in 2018.

Market Dynamics

Drivers

• Increase in Outbreaks of Meningococcal Disease
• Surge in Immunization Programs Across the Globe
• Increase in Research and Development for Vaccine Technology

Restraint

• Longer Timelines Required for Vaccine Production
• High Costs Associated With the Development of Vaccines

Opportunities

• Growth Opportunities in the Emerging Markets
• Increase in Healthcare Spending
• Increase in Research and Development for Meningococcal Vaccines

Key Players Profiled

• Bio-Manguinhos
• Bio-Med Pvt. Limited
• Chongqing Zhifei Biological Products Co., Ltd.
• GlaxoSmithKline Plc
• Hualan Biological Engineering Inc.
• Incepta Pharmaceuticals Ltd.
• Pfizer INC
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd
• Walvax Biotechnology Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/dwjcj6

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900